Ligand Announces Positive Top Line Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol July 10, 2019
Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation July 8, 2019
ZULRESSO™ (brexanolone) CIV, a Product for Treating Postpartum Depression Using Ligand’s Captisol® in its Formulation, Launched by Sage Therapeutics July 1, 2019
Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology Target June 12, 2019
